94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Pharmacol.
Sec. Neuropharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1553337
The prospective approach for aptamers applied in the treatment and molecular diagnostics of ischemic stroke
Provisionally accepted- 1Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- 2Wuhan University, Wuhan, Hubei Province, China
- 3Beijing Huilongguan Hospital, Peking University, Beijing, Beijing Municipality, China
- 4Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province, China
- 5Department of Immunology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Ischemic stroke is a leading cause of death and disability worldwide. Therefore, there is a critical need to explore the underlying mechanisms and develop effective treatment strategies for ischemic stroke. As small and non-immunogenic nucleic acid molecules, aptamers can be easily chemically modified, break through the blood-brain barrier, and be screened using the classic Systematic Evolution of Ligands by Exponential Enrichment. With the advancements in emerging technologies, aptamer-based strategies have provided diagnostic and therapeutic potential for applications in central nervous system diseases. Aptamers have become a useful tool for targeted therapy and biomarker discovery in ischemic stroke. This review presents recent advances and perspectives on aptamer applications in stroke prevention, treatment, and diagnosis, focusing on targeting pathological blood clotting or thrombosis, inflammatory responses, and specific biomarkers in key cells.
Keywords: aptamer, SELEX, ischemic stroke, Central Nervous System, targeted therapy, Molecular diagnostics
Received: 10 Mar 2025; Accepted: 10 Apr 2025.
Copyright: © 2025 Li, Wu, Hu, Zhang, Ye, Luo, Zeng and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yi Luo, Zhongnan Hospital, Wuhan University, Wuhan, 430071, Hubei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.